Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 3/20 | 0.47 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105751 | 0.83 | ACHE (0.60) | ACHESIGMAR1MC4R | |
| SCHEMBL692536 | 0.83 | ACHE (0.60) | ACHESIGMAR1MC4R | |
| SCHEMBL5766167 | 0.83 | ACHE (0.60) | ACHESIGMAR1MC4R | |
| SCHEMBL467266 | 0.83 | TACR1 (0.62) | ACHEGAASIGMAR1TACR1MC4R | |
| SCHEMBL6943959 | 0.83 | TACR1 (0.62) | ACHEGAASIGMAR1TACR1MC4R | |
| SCHEMBL385325 | 0.83 | TACR1 (0.62) | ACHEGAASIGMAR1TACR1MC4R | |
| SCHEMBL1920327 | 0.82 | FUCA1 (0.53) | ACHEGAASIGMAR1TACR1FUCA1 | |
| SCHEMBL8294589 | 0.82 | ACHE (0.53) | ACHEGAASIGMAR1TACR1FUCA1 | |
| SCHEMBL654452 | 0.82 | FUCA1 (0.53) | ACHEGAASIGMAR1TACR1FUCA1 | |
| SCHEMBL12533691 | 0.82 | FUCA1 (0.53) | ACHEGAASIGMAR1TACR1FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| EP-0562042-A4 | QUINOLINE, NAPHTHYRIDINE AND PYRIDOBENZOXAZINE DERIVATIVES | ABBOTT LAB (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0562042-A1 | QUINOLINE, NAPHTHYRIDINE AND PYRIDOBENZOXAZINE DERIVATIVES | ABBOTT LABORATORIES (US) | 1993-09-29 | — | — | EP | disclosed |
| CN-1019114-B | QUINOLINE-3-CARBOXYLIC ACID DERIVATIVES AND THE PREPN. METHOD THEREOF | SANKYO CO (JP) | 1992-11-18 | — | — | CN | disclosed |
| US-5137892-A | Bactericides | ABBOTT LABORATORIES (US) | 1992-08-11 | — | — | US | disclosed |
| WO-1992010191-A1 | QUINOLINE, NAPHTHYRIDINE AND PYRIDOBENZOXAZINE DERIVATIVES | ABBOTT LABORATORIES (US) | 1992-06-25 | — | — | WO | disclosed |
| US-4997943-A | Bactericides | SANKYO COMPANY LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| CN-1010312-B | PYRIDONECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR PREPARING SAME | KYORIN SEIYAKU KK (JP) | 1990-11-07 | — | — | CN | disclosed |
| EP-0208210-B1 | PYRIDONECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4753953-A | Pyridonecarboxylic acid derivatives and antibacterial pharmaceutical compositions thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0241206-A2 | Quinoline-3-carboxylic acid derivatives, their preparation and use | Sankyo Company Limited (JP) | 1987-10-14 | — | — | EP | disclosed |
| CN-86104479-A | The preparation method of pyridone carboxylic acid derivatives | — | 1987-02-04 | — | — | CN | disclosed |
| EP-0208210-A1 | Pyridonecarboxylic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-01-14 | — | — | EP | disclosed |
| US-4210660-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, ESPECIALLY ANTIPSYCOTICS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | ACHE 1062/4885GAA 4539/4885SIGMAR1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.